Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 208

Sort by

Sort Order Select

Journal Articles

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Blood (2024) 144 (1): 61–73.

https://doi.org/10.1182/blood.2024023930

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Elias Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney DiNardo, Lucia Masarova, Tapan Kadia, Rebecca S. Garris, Farhad Ravandi, Hagop Kantarjian

Blood (2024) 143 (5): 417–421.

https://doi.org/10.1182/blood.2023022330

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 833.

https://doi.org/10.1182/blood-2023-172658

Published: 2023

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4289.

https://doi.org/10.1182/blood-2023-182901

Published: 2023

Journal Articles

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Blood (2023) 142 (Supplement 1): 58.

https://doi.org/10.1182/blood-2023-182337

Published: 2023

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Alex Bataller, Danielle E. Hammond, Kelly S. Chien, Courtney D. DiNardo, Nicholas J. Short, Abhishek Maiti, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2922.

https://doi.org/10.1182/blood-2023-185191

Published: 2023

Journal Articles

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Guillermo Montalban-Bravo, Elias Jabbour, Kelly S. Chien, Danielle E. Hammond, Nicholas J. Short, Farhad Ravandi, Marina Y. Konopleva, Gautam Borthakur, Naval Daver, Rashmi Kanagal-Shamanna, Wei Qiao, Xuelin Huang, Heather Schneider, Meghan Anne Meyer, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2023-178115

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2023) 142 (Supplement 1): 322.

https://doi.org/10.1182/blood-2023-190693

Published: 2023

Journal Articles

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Yesid Alvarado-Valero, Lucia Masarova, Mark Brandt, Debra Bull-Linderman, Naval Daver, Guillermo Montalban-Bravo, Alex Bataller, Guillermo Garcia-Manero, Ghayas C. Issa, Amin Alousi, Nicholas J. Short, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2023-182969

Published: 2023

Journal Articles

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Guilin Tang, Fadi G. Haddad, Nitin Jain, Ghayas C. Issa, Tapan M. Kadia, Naval Daver, Alessandra Ferrajoli, Monica Kwari, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Patrice Eric Nasnas, Naveen Pemmaraju, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian

Blood (2023) 142 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2023-181379

Published: 2023

Journal Articles

Fludarabine, Cytarabine (ARA-C) and Pegylated Erwinase (PEGCRISANTASPASE) in Patients with Relapsed or Refractory Leukemia

Emmanuel Almanza, Alex Bataller, Guillermo Garcia-Manero, Abhishek Maiti, Guillermo Montalban-Bravo, Koichi Takahashi, Nicholas J. Short, Elias Jabbour, Farhad Ravandi, Yesid Alvarado Valero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 5971.

https://doi.org/10.1182/blood-2023-191239

Published: 2023

Journal Articles

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Guillermo Montalban-Bravo, Nicholas J. Short, Kelly S. Chien, Yesid Alvarado Valero, Naval Daver, Gautam Borthakur, Mahesh Swaminathan, Abhishek Maiti, Danielle E. Hammond, Graciela Nogueras-Gonzalez, Xuelin Huang, Heather Schneider, Kristen Shelly, Tapan M. Kadia, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 1876.

https://doi.org/10.1182/blood-2023-178035

Published: 2023

Journal Articles

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Jayastu Senapati, Sanam Loghavi, Patrick K Reville, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Elias Jabbour, Nicholas J. Short, Naveen Pemmaraju, Abhishek Maiti, Ghayas C. Issa, Uday R. Popat, Amin Alousi, Elizabeth J. Shpall, Koji Sasaki, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2023-179380

Published: 2023

Journal Articles

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Georgina Gener-Ricos, Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G. Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia-Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2023-187795

Published: 2023

Journal Articles

Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 959.

https://doi.org/10.1182/blood-2023-188319

Published: 2023

Journal Articles

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yilmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masarova, Debra Bull-Linderman, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2023-172883

Published: 2023

NARROW

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Phase II Trial of 10-Day ASTX727 (Decitabine/Cedazuridine) with Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL Mutations

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Fludarabine, Cytarabine (ARA-C) and Pegylated Erwinase (PEGCRISANTASPASE) in Patients with Relapsed or Refractory Leukemia

Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results

Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only